Dr. John Oldenhof is the Executive VP Scientific Affairs at BioPharma Services. John joined the BioPharma team in 2018 and brings with him 18 years of senior management experience in Phase I clinical pharmacology, product development, biostatistics, data management and regulatory and scientific affairs. His published work and experience includes the development of novel methodologies, innovative study designs and direct collaboration with the US Food and Drug Administration (FDA) to advance human abuse potential studies and pharmacometrics analyses.
Over his tenure in Clinical Pharmacology, Dr. Oldenhof has provided scientific and regulatory guidance to biotech and pharmaceutical sponsors on over 300 clinical pharmacology studies including FIM, SAD/MAD, DDI and TQT studies to support pre-IND, NDA, ANDA and product launches.
Dr. Oldenhof holds an Adjunct Lecturer position in the Department of Pharmacology & Toxicology at the University of Toronto and is a parent advocate of the Genetic Epilepsy STXBP1 Disorder Scientific Advisory Board. The disease is an ultra rare genetic epilepsy with developmental delay and autism. Dr. Oldenhof has been actively working in the community and with the FDA.
Recent Comments